ANAVEX LIFE SCIENCES CORP. - 8-K Filing

Anavex Life Sciences completed clinical conduct of ADME and DDI studies for blarcamesine, with no serious adverse events reported. (Items: 8.01 Other Events)

SEC EDGAR · October 20, 2026, 20:17 UTC

Tickers: $AVXL

Read the full article at SEC EDGAR

Part of the story ANAVEX LIFE SCIENCES CORP. - 8-K Filing (3 articles)

More Regulatory news

Solana Co - 10-Q Filing SEC EDGAR · November 12, 2026, 13:42 UTC
Solana Co - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
DeFi Development Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
Stablecoin Development Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:40 UTC
BCP Investment Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:36 UTC
OneWater Marine Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Moleculin Biotech, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Investcorp Credit Management BDC, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Presurance Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:35 UTC
Corteva, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:34 UTC